WO2001015676A2 - Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides - Google Patents

Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides Download PDF

Info

Publication number
WO2001015676A2
WO2001015676A2 PCT/IB2000/001492 IB0001492W WO0115676A2 WO 2001015676 A2 WO2001015676 A2 WO 2001015676A2 IB 0001492 W IB0001492 W IB 0001492W WO 0115676 A2 WO0115676 A2 WO 0115676A2
Authority
WO
WIPO (PCT)
Prior art keywords
abcl
compound
biological activity
candidate compound
disease
Prior art date
Application number
PCT/IB2000/001492
Other languages
English (en)
Other versions
WO2001015676A3 (fr
WO2001015676A9 (fr
Inventor
Michael R. Hayden
Angela R. Brooks-Wilson
Simon N. Pimstone
Susanne M. Clee
Original Assignee
University Of British Columbia
Xenon Genetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/526,193 external-priority patent/US6617122B1/en
Application filed by University Of British Columbia, Xenon Genetics, Inc. filed Critical University Of British Columbia
Priority to EP00974705A priority Critical patent/EP1239848A2/fr
Priority to JP2001519890A priority patent/JP2003520780A/ja
Priority to AU12919/01A priority patent/AU1291901A/en
Priority to CA002382562A priority patent/CA2382562A1/fr
Publication of WO2001015676A2 publication Critical patent/WO2001015676A2/fr
Publication of WO2001015676A3 publication Critical patent/WO2001015676A3/fr
Publication of WO2001015676A9 publication Critical patent/WO2001015676A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

L'invention concerne des méthodes permettant de traiter des patients ayant un faible taux de HDL cholestérol, un taux de triglycérides supérieur à la normale ou une maladie cardio-vasculaire, en leur administrant des composés qui modulent l'expression ou l'activité de ABC1.
PCT/IB2000/001492 1999-09-01 2000-09-01 Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides WO2001015676A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00974705A EP1239848A2 (fr) 1999-09-01 2000-09-01 Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides
JP2001519890A JP2003520780A (ja) 1999-09-01 2000-09-01 Ｈｄｌコレステロールとトリグリセリド水準を調節する組成物と方法
AU12919/01A AU1291901A (en) 1999-09-01 2000-09-01 Compositions and methods for modulating hdl cholesterol and triglyceride levels
CA002382562A CA2382562A1 (fr) 1999-09-01 2000-09-01 Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15197799P 1999-09-01 1999-09-01
US60/151,977 1999-09-01
US09/526,193 2000-03-15
US09/526,193 US6617122B1 (en) 1999-03-15 2000-03-15 Process for identifying modulators of ABC1 activity
US21395800P 2000-06-23 2000-06-23
US60/213,958 2000-06-23

Publications (3)

Publication Number Publication Date
WO2001015676A2 true WO2001015676A2 (fr) 2001-03-08
WO2001015676A3 WO2001015676A3 (fr) 2002-07-25
WO2001015676A9 WO2001015676A9 (fr) 2003-06-19

Family

ID=27387196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/001492 WO2001015676A2 (fr) 1999-09-01 2000-09-01 Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides

Country Status (5)

Country Link
EP (1) EP1239848A2 (fr)
JP (1) JP2003520780A (fr)
AU (1) AU1291901A (fr)
CA (1) CA2382562A1 (fr)
WO (1) WO2001015676A2 (fr)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001082917A2 (fr) * 2000-05-03 2001-11-08 Tularik Inc. Traitement de l'hypertriglyceridemie et d'autres maladies au moyen de modulateurs lxr
WO2001083746A2 (fr) * 2000-05-02 2001-11-08 Aventis Pharma S.A. Acide nucleique regulateur pour le gene abc1, molecule modifiant son activite et applications therapeutiques
WO2002012342A2 (fr) * 2000-08-04 2002-02-14 Genaissance Pharmaceuticals, Inc. Haplotypes du gene edg4
WO2002011708A2 (fr) * 2000-08-04 2002-02-14 Symphar S.A. Procedes d'induction de la secretion d'apolipoproteine e
WO2002081691A2 (fr) * 2000-11-20 2002-10-17 Tularik Inc. Abcg5 et abcg8: compositions et procedes d'utilisation
WO2002097123A2 (fr) * 2001-05-25 2002-12-05 Xenon Genetics, Inc. Procedes de diagnostic de maladies cardio-vasculaires, faibles niveaux de cholesterol ldl, et niveaux eleves de triglyceride
US6821774B1 (en) 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
US6835563B1 (en) 1999-06-18 2004-12-28 Cv Therapeutics Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
EP1511483A2 (fr) * 2002-03-27 2005-03-09 Smithkline Beecham Corporation Procedes de traitement au moyen de modulateurs lxr
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US7265131B2 (en) 2002-12-20 2007-09-04 Exelixis, Inc. Isoquinolinone derivatives and their use as therapeutic agents
WO2008062830A1 (fr) 2006-11-24 2008-05-29 Hykes Laboratories Llc Composé de spiroquinone et composition pharmaceutique
WO2008115469A2 (fr) * 2007-03-16 2008-09-25 The Regents Of The University Of California Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires
JP2009519001A (ja) * 2002-12-20 2009-05-14 アプレラ コーポレイション 狭窄に関連する遺伝的多型、その検出方法および使用
US20100273761A1 (en) * 2004-10-25 2010-10-28 Shunlin Ren Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US7897588B2 (en) 2002-08-29 2011-03-01 The Regents Of The University Of California Agents and methods for enhancing bone formation
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US8013001B2 (en) 2001-12-21 2011-09-06 Exelixis, Inc. Modulators of LXR
US8022052B2 (en) 2006-12-19 2011-09-20 The Regents Of The University Of California Inhibition of PPAR gamma expression by specific osteogenic oxysterols
AU2011299762B2 (en) * 2010-09-07 2014-03-06 Delaval Holding Ab A cabinet in a milking parlour
WO2015025180A1 (fr) * 2013-08-23 2015-02-26 Glasgow Caledonian University Modulation du cholestérol
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
US9526737B2 (en) 2007-12-03 2016-12-27 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
US9670244B2 (en) 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
US9683009B2 (en) 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
US9717742B2 (en) 2012-05-07 2017-08-01 The Regents Of The University Of California Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
US10144759B2 (en) 2004-10-25 2018-12-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US10272097B2 (en) 2013-12-24 2019-04-30 Virginia Commonwealth University Uses of oxygenated cholesterol sulfates (OCS)
US11406646B2 (en) 2016-08-02 2022-08-09 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8317674B2 (en) 2008-06-11 2012-11-27 Bracco Diagnostics Inc. Shielding assemblies for infusion systems
EP2328635B1 (fr) 2008-06-11 2019-10-16 Bracco Diagnostics Inc. Configurations de structure en coffret pour systèmes de perfusion
US11752254B2 (en) 2016-09-20 2023-09-12 Bracco Diagnostics Inc. Radioisotope delivery system with multiple detectors to detect gamma and beta emissions
CA3094463A1 (fr) 2018-03-28 2019-10-03 Bracco Diagnostics Inc. Detection precoce de la duree de vie d'un generateur de radio-isotopes

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152152A (en) * 1962-06-21 1964-10-06 Upjohn Co 24-dehydro cholesterol analogs and the process for the preparation thereof
WO1997012853A1 (fr) * 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Modulateurs rxr selectifs pour les dimeres et leurs methodes d'utilisation
WO1997042215A1 (fr) * 1996-05-06 1997-11-13 Bionumerik Pharmaceuticals, Inc. Procede de preparation de 27-hydroxy cholesterol et de derives apparentes
WO1998057647A1 (fr) * 1997-06-18 1998-12-23 Baylor College Of Medicine Recepteur nucleaire orphelin, coup-tfii, necessaire a l'angiogenese
US5929062A (en) * 1997-06-19 1999-07-27 University Of Western Ontario Oxysterol inhibition of dietary cholesterol uptake
WO2000034461A2 (fr) * 1998-12-10 2000-06-15 Board Of Regents, The University Of Texas System Compositions et techniques de modulation du metabolisme du cholesterol
WO2000054759A2 (fr) * 1999-03-15 2000-09-21 Tularik Inc. Modulateurs du lxr
WO2000055318A2 (fr) * 1999-03-15 2000-09-21 University Of British Columbia Methodes et reactifs permettant de moduler les taux de cholesterol
WO2000078971A2 (fr) * 1999-06-18 2000-12-28 Cv Therapeutics, Inc. Compositions et procedes visant a augmenter la sortie de cholesterol et a augmenter la hdl au moyen de la proteine de transport de cassettes de liaison d'atp abc1
WO2001003705A1 (fr) * 1999-07-08 2001-01-18 Tularik Inc. Compositions et methodes permettant d'augmenter les taux de hdl cholesterol
WO2001032184A2 (fr) * 1999-11-01 2001-05-10 Wisconsin Alumni Research Foundation Gene de transport de cholesterol
WO2001041704A2 (fr) * 1999-12-13 2001-06-14 Merck & Co., Inc. Procede de prevention et/ou de traitement de l'atherosclerose
WO2001066098A2 (fr) * 2000-03-09 2001-09-13 Aventis Pharma Deutschland Gmbh Utilisations therapeutiques des mediateurs ppar
WO2001083746A2 (fr) * 2000-05-02 2001-11-08 Aventis Pharma S.A. Acide nucleique regulateur pour le gene abc1, molecule modifiant son activite et applications therapeutiques

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152152A (en) * 1962-06-21 1964-10-06 Upjohn Co 24-dehydro cholesterol analogs and the process for the preparation thereof
WO1997012853A1 (fr) * 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Modulateurs rxr selectifs pour les dimeres et leurs methodes d'utilisation
WO1997042215A1 (fr) * 1996-05-06 1997-11-13 Bionumerik Pharmaceuticals, Inc. Procede de preparation de 27-hydroxy cholesterol et de derives apparentes
WO1998057647A1 (fr) * 1997-06-18 1998-12-23 Baylor College Of Medicine Recepteur nucleaire orphelin, coup-tfii, necessaire a l'angiogenese
US5929062A (en) * 1997-06-19 1999-07-27 University Of Western Ontario Oxysterol inhibition of dietary cholesterol uptake
WO2000034461A2 (fr) * 1998-12-10 2000-06-15 Board Of Regents, The University Of Texas System Compositions et techniques de modulation du metabolisme du cholesterol
WO2000054759A2 (fr) * 1999-03-15 2000-09-21 Tularik Inc. Modulateurs du lxr
WO2000055318A2 (fr) * 1999-03-15 2000-09-21 University Of British Columbia Methodes et reactifs permettant de moduler les taux de cholesterol
WO2000078971A2 (fr) * 1999-06-18 2000-12-28 Cv Therapeutics, Inc. Compositions et procedes visant a augmenter la sortie de cholesterol et a augmenter la hdl au moyen de la proteine de transport de cassettes de liaison d'atp abc1
WO2001003705A1 (fr) * 1999-07-08 2001-01-18 Tularik Inc. Compositions et methodes permettant d'augmenter les taux de hdl cholesterol
WO2001032184A2 (fr) * 1999-11-01 2001-05-10 Wisconsin Alumni Research Foundation Gene de transport de cholesterol
WO2001041704A2 (fr) * 1999-12-13 2001-06-14 Merck & Co., Inc. Procede de prevention et/ou de traitement de l'atherosclerose
WO2001066098A2 (fr) * 2000-03-09 2001-09-13 Aventis Pharma Deutschland Gmbh Utilisations therapeutiques des mediateurs ppar
WO2001083746A2 (fr) * 2000-05-02 2001-11-08 Aventis Pharma S.A. Acide nucleique regulateur pour le gene abc1, molecule modifiant son activite et applications therapeutiques

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ACCAD M ET AL: "CHOLESTEROL HOMEOSTASIS: A ROLE FOR OXYSTEROLS" CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 8, no. 17, 27 August 1998 (1998-08-27), pages R601-R604, XP001015383 ISSN: 0960-9822 *
COSTET P ET AL: "STEROL-DEPENDENT TRANSACTIVATION OF THE ABC1 PROMOTER BY THE LIVER X RECEPTOR/RETINOID X RECEPTOR" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 36, 8 September 2000 (2000-09-08), pages 28240-28245, XP000972366 ISSN: 0021-9258 *
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; January 1999 (1999-01) BRENDEL CAROLE ET AL: "Transcriptional regulation of cholesterol metabolism." Database accession no. PREV199900152920 XP002176374 -& M-S (MEDECINE SCIENCES), vol. 15, no. 1, January 1999 (1999-01), pages 56-62, XP001016141 ISSN: 0767-0974 *
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TABATA, TOSHIKAZU ET AL: "Hypocholesterolemic activity of phytosterol. II" retrieved from STN Database accession no. 93:160958 XP002175493 & YAKUGAKU ZASSHI (1980), 100(5), 546-52, *
JANOWSKI ET AL: "An oxysterol signalling pathway mediated by the nuclear receptor LXR.alpha" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 383, no. 6602, 24 October 1996 (1996-10-24), pages 728-731, XP002104644 ISSN: 0028-0836 *
JANOWSKI ET AL: "Structural requirements of ligands for the oxysterol liver X receptors LXR.alpha. and LXR.beta" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 1, 5 January 1999 (1999-01-05), pages 266-271, XP002104645 ISSN: 0027-8424 cited in the application *
KRUT L H: "CLEARANCE OF SUB CUTANEOUS IMPLANTS OF CHOLESTEROL IN THE RAT PROMOTED BY OXIDATION PRODUCTS OF CHOLESTEROL A POSTULATED ROLE FOR OXY STEROLS IN PREVENTING ATHERO SCLEROSIS" ATHEROSCLEROSIS, vol. 43, no. 1, 1982, pages 105-118, XP001016481 ISSN: 0021-9150 *
LANGMANN T ET AL: "MOLECULAR CLONING OF THE HUMAN ATP-BINDING CASSETTE TRANSPORTER 1 (HABC1): EVIDENCE FOR STEROL-DEPENDENT REGULATION IN MACROPHAGES" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 257, no. 1, 2 April 1999 (1999-04-02), pages 29-33, XP000877240 ISSN: 0006-291X *
LAWN R M ET AL: "THE TANGIER DISEASE GENE PRODUCT ABC1 CONTROLS THE CELLULAR APOLIPOPROTEIN-MEDIATED LIPID REMOVAL PATHWAY" JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 104, no. 8, October 1999 (1999-10), pages R25-R31, XP000884782 ISSN: 0021-9738 *
LEHMANN JUERGEN M ET AL: "Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 6, 1997, pages 3137-3140, XP001015265 ISSN: 0021-9258 *
RUST S ET AL: "TANGIER DISEASE IS CAUSED BY MUTATIONS IN THE GENE ENCODING ATP--BINDING CASSETTE TRANSPORTER 1" NATURE GENETICS, NEW YORK, NY, US, vol. 22, no. 4, August 1999 (1999-08), pages 352-355, XP000884993 ISSN: 1061-4036 *
SANTAMARINA-FOJO S ET AL: "COMPLETE GENOMIC SEQUENCE OF THE HUMAN ABCA1 GENE: ANALYSIS OF THE HUMAN AND MOUSE ATP-BINDING CASSETTE A PROMOTER" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 14, 5 July 2000 (2000-07-05), pages 7987-7992, XP000946151 ISSN: 0027-8424 *
SCHROEPFER, GEORGE J., JR.: "Design of new oxysterols for regulation of cholesterol metabolism" CURR. PHARM. DES. (1996), 2(1), 103-120, XP001014779 *
SCHWARTZ K ET AL: "ABC1 GENE EXPRESSION AND APOA-I-MEDIATED CHOLESTER0L EFFLUX ARE REGULATED BY LXR" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 274, no. 3, 11 August 2000 (2000-08-11), pages 794-802, XP000960872 ISSN: 0006-291X *

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821774B1 (en) 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
US6835563B1 (en) 1999-06-18 2004-12-28 Cv Therapeutics Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
US7378274B2 (en) 2000-05-02 2008-05-27 Aventis Pharma S.A. Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses
FR2809414A1 (fr) * 2000-05-02 2001-11-30 Aventis Pharma Sa Acide nucleique regulateur du gene abc1, molecules modulant son activite et applications therapeutiques
WO2001083746A3 (fr) * 2000-05-02 2002-06-27 Aventis Pharma Sa Acide nucleique regulateur pour le gene abc1, molecule modifiant son activite et applications therapeutiques
WO2001083746A2 (fr) * 2000-05-02 2001-11-08 Aventis Pharma S.A. Acide nucleique regulateur pour le gene abc1, molecule modifiant son activite et applications therapeutiques
WO2001082917A3 (fr) * 2000-05-03 2002-06-06 Tularik Inc Traitement de l'hypertriglyceridemie et d'autres maladies au moyen de modulateurs lxr
WO2001082917A2 (fr) * 2000-05-03 2001-11-08 Tularik Inc. Traitement de l'hypertriglyceridemie et d'autres maladies au moyen de modulateurs lxr
WO2002012342A3 (fr) * 2000-08-04 2003-08-28 Genaissance Pharmaceuticals Haplotypes du gene edg4
WO2002012342A2 (fr) * 2000-08-04 2002-02-14 Genaissance Pharmaceuticals, Inc. Haplotypes du gene edg4
WO2002011708A3 (fr) * 2000-08-04 2003-03-13 Symphar Sa Procedes d'induction de la secretion d'apolipoproteine e
WO2002011708A2 (fr) * 2000-08-04 2002-02-14 Symphar S.A. Procedes d'induction de la secretion d'apolipoproteine e
WO2002081691A2 (fr) * 2000-11-20 2002-10-17 Tularik Inc. Abcg5 et abcg8: compositions et procedes d'utilisation
WO2002081691A3 (fr) * 2000-11-20 2003-07-03 Tularik Inc Abcg5 et abcg8: compositions et procedes d'utilisation
WO2002097123A2 (fr) * 2001-05-25 2002-12-05 Xenon Genetics, Inc. Procedes de diagnostic de maladies cardio-vasculaires, faibles niveaux de cholesterol ldl, et niveaux eleves de triglyceride
WO2002097123A3 (fr) * 2001-05-25 2003-08-21 Xenon Genetics Inc Procedes de diagnostic de maladies cardio-vasculaires, faibles niveaux de cholesterol ldl, et niveaux eleves de triglyceride
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US8013001B2 (en) 2001-12-21 2011-09-06 Exelixis, Inc. Modulators of LXR
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
EP1511483A2 (fr) * 2002-03-27 2005-03-09 Smithkline Beecham Corporation Procedes de traitement au moyen de modulateurs lxr
EP1511483A4 (fr) * 2002-03-27 2009-03-18 Smithkline Beecham Corp Procedes de traitement au moyen de modulateurs lxr
US7897588B2 (en) 2002-08-29 2011-03-01 The Regents Of The University Of California Agents and methods for enhancing bone formation
US7265131B2 (en) 2002-12-20 2007-09-04 Exelixis, Inc. Isoquinolinone derivatives and their use as therapeutic agents
JP2009519001A (ja) * 2002-12-20 2009-05-14 アプレラ コーポレイション 狭窄に関連する遺伝的多型、その検出方法および使用
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
US20100273761A1 (en) * 2004-10-25 2010-10-28 Shunlin Ren Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US11384115B2 (en) 2004-10-25 2022-07-12 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US10844089B2 (en) 2004-10-25 2020-11-24 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US10144759B2 (en) 2004-10-25 2018-12-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9321802B2 (en) 2004-10-25 2016-04-26 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9670244B2 (en) 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
WO2008062830A1 (fr) 2006-11-24 2008-05-29 Hykes Laboratories Llc Composé de spiroquinone et composition pharmaceutique
US8119686B2 (en) 2006-11-24 2012-02-21 Hykes Laboratories Llc Spiroquinone compound and pharmaceutical composition
US8022052B2 (en) 2006-12-19 2011-09-20 The Regents Of The University Of California Inhibition of PPAR gamma expression by specific osteogenic oxysterols
WO2008115469A2 (fr) * 2007-03-16 2008-09-25 The Regents Of The University Of California Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires
WO2008115469A3 (fr) * 2007-03-16 2009-12-03 The Regents Of The University Of California Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires
US9526737B2 (en) 2007-12-03 2016-12-27 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
AU2011299762B2 (en) * 2010-09-07 2014-03-06 Delaval Holding Ab A cabinet in a milking parlour
US9480692B2 (en) 2011-04-06 2016-11-01 Virginia Commonwealth University Sulfated-oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
US9717742B2 (en) 2012-05-07 2017-08-01 The Regents Of The University Of California Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
US9683009B2 (en) 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
WO2015025180A1 (fr) * 2013-08-23 2015-02-26 Glasgow Caledonian University Modulation du cholestérol
US10272097B2 (en) 2013-12-24 2019-04-30 Virginia Commonwealth University Uses of oxygenated cholesterol sulfates (OCS)
US10786517B2 (en) 2013-12-24 2020-09-29 Durect Corporation Uses of oxygenated cholesterol sulfates (OCS)
US11612609B2 (en) 2013-12-24 2023-03-28 Durect Corporation Uses of oxygenated cholesterol sulfates (OCS)
US11406646B2 (en) 2016-08-02 2022-08-09 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Also Published As

Publication number Publication date
WO2001015676A3 (fr) 2002-07-25
WO2001015676A9 (fr) 2003-06-19
EP1239848A2 (fr) 2002-09-18
AU1291901A (en) 2001-03-26
JP2003520780A (ja) 2003-07-08
CA2382562A1 (fr) 2001-03-08

Similar Documents

Publication Publication Date Title
WO2001015676A2 (fr) Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides
US8067219B2 (en) Polynucleotide encoding an ATP binding cassette transporter 1 (ABC1) polypeptide
JP4586005B2 (ja) 新規なステロイド活性化核受容体とその利用法
US6545137B1 (en) Receptor
FR2767135A1 (fr) Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
US6225451B1 (en) Chromosome 11-linked coronary heart disease susceptibility gene CHD1
US20060014940A1 (en) Cloning and characterization of slc26a6, slc26a1, and slc26a2 anion exchangers
US6555654B1 (en) LDL-receptor
US20030181660A1 (en) Novel LDL-receptor
JP2003523177A (ja) ヒトａｂｃ１遺伝子の核酸、並びに治療及び予防へのそれらの適用
EP1854880A1 (fr) Procédés et réactifs pour moduler les niveaux de cholestérol
US6544743B1 (en) Peroxisome proliferator-activated receptor alpha and disorders of lipid metabolism
JP2002512041A (ja) 緑内障および前眼部形成不全の診断および予後判定のためのｆｒｅａｃ３遺伝子における新規変異
US20050136421A1 (en) Methods and reagents for modulating cholesterol levels
EP1227818A2 (fr) Gene de transport de cholesterol
CA2407737A1 (fr) Acide nucleique regulateur pour le gene abc1, molecule modifiant son activite et applications therapeutiques
KR20020012279A (ko) 인간 유전자 에이비씨1에 상응하는 핵산 및 단백질
WO1998043666A1 (fr) Proteine anti-oxydante 2, gene et procedes d'utilisation correspondants
Vaessen et al. Efficient lowering of triglyceride levels in mice by human apoAV protein variants associated with hypertriglyceridemia
WO2006055927A2 (fr) Gene et proteine pathogenes associes a la dyskinesie paroxystique et a l'epilepsie
JP2001518312A (ja) 血圧調節およびｉｉｉ型バーター症候群を診断する方法
US20020142417A1 (en) Antioxidant protein 2, gene and methods of use therefor
WO1999045112A2 (fr) Gene chd1 de susceptibilite aux maladies coronariennes lie au chromosome 11
FR2767136A1 (fr) Recepteur complexe lsr, activite, clonage, et applications au diagnostic, a la prevention et/ou au traitement de l'obesite et des risques ou complications associes
WO2004003159A2 (fr) Nouvelle cible therapeutique pour le traitement de maladies vasculaires, de dyslipidemies et de troubles associes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2382562

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 519890

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000974705

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12919/01

Country of ref document: AU

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000974705

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 46 AND 48, DESCRIPTION, REPLACED BY NEW PAGES 46 AND 48; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY

WWW Wipo information: withdrawn in national office

Ref document number: 2000974705

Country of ref document: EP